二甲双胍用于晚期卵巢癌患者:一项随机II期安慰剂对照试验
该随机II期安慰剂对照试验纳入108例可评估的晚期卵巢癌患者,1:1随机接受一线铂/紫杉类化疗联合二甲双胍850mg每日两次或安慰剂,并维持治疗两年。主要终点无进展生存期(PFS)在两组间无显著差异(单侧P=0.31;校正HR=0.87,95%CI 0.56-1.36),总生存期(OS)亦无显著差异(双侧P=0.21;校正HR=1.49,95%CI 0.86-2.59)。二甲双胍耐受良好,两组毒性无差异。
要点
- 二甲双胍联合一线铂/紫杉类化疗并维持治疗未改善晚期卵巢癌患者的PFS(校正HR=0.87,95%CI 0.56-1.36)。
- 总生存期在二甲双胍组与安慰剂组间无显著差异(校正HR=1.49,95%CI 0.86-2.59)。
- 二甲双胍耐受良好,两组间毒性无差异。
核心结论
- 尽管二甲双胍耐受良好,但在新诊断晚期卵巢癌患者的一线铂/紫杉类治疗中加入二甲双胍并未改善PFS或OS。
研究设计与样本
- 随机II期安慰剂对照试验,纳入病理确诊的晚期卵巢癌患者,接受初次肿瘤细胞减灭术或新辅助铂类化疗后手术。
- 患者1:1随机接受铂/紫杉类化疗联合二甲双胍850mg口服每日两次或安慰剂,并从随机化日期起维持治疗两年。
- 共108例可评估患者入组,二甲双胍组54例,安慰剂组54例。
主要发现
- 66%(n=71)接受新辅助治疗,31%(n=33)接受初次肿瘤细胞减灭术,88%(n=93)为高级别浆液性组织学肿瘤。
- 主要终点PFS在治疗组间无显著差异(单侧P=0.31;校正HR=0.87,95%CI 0.56-1.36)。
- OS无显著差异(双侧P=0.21;校正HR=1.49,95%CI 0.86-2.59),二甲双胍组中位OS为40.7个月(95%CI 28.0-48.2),安慰剂组为43.8个月(95%CI 35.3-57.2)。
- 加用二甲双胍耐受良好,两组间毒性无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The primary aim of this study was to determine if metformin, an oral biguanide administered with first-line chemotherapy and continued as maintenance therapy, improves progression-free survival (PFS) for patients with advanced-stage ovarian cancer. METHODS: Patients with pathologically confirmed advanced-stage ovarian cancer undergoing primary debulking or neoadjuvant platinum-based chemotherapy followed by surgery were eligible to participate. Patients were randomized 1:1 to receive platinum/taxane-based chemotherapy with metformin 850 mg orally twice per day or placebo, followed by maintenance therapy (metformin or placebo) for two years from the date of randomization. RESULTS: 108 evaluable patients were enrolled; 54 were randomly assigned to metformin, and 54 to placebo. Sixty-six percent (n = 71) received neoadjuvant therapy, 31 % (n = 33) primary debulking surgery, and 88 % (n = 93) had tumors of high-grade serous histology. The primary endpoint, PFS, was not significantly different between the treatment groups (1-sided p-value = 0.31; adjusted hazard ratio [HR] = 0.87, 95 % confidence interval [CI]: 0.56-1.36). Median PFS was 15.4 months (95 % CI: 11.2-23,5) for metformin and 14.3 months (95 % CI: 11.6-18.0) for placebo. Overall survival (OS) was not significantly different (2-sided p-value = 0.21; adjusted HR = 1.49, 95 % CI: 0.86-2.59), with a median of 40.7 months (95 % CI: 28.0-48.2) for metformin versus 43.8 months (95 % CI: 35.3-57.2) for placebo. The addition of metformin was well tolerated, and there were no differences in toxicity between the two groups. CONCLUSION: Although it was well-tolerated, adding metformin to first-line platinum/taxane-based therapy does not improve PFS or OS for patients with newly diagnosed advanced stage ovarian cancer.
引用
- Romero IL, Lengyel E, Wahner Hendrickson AE, et al. Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025. PMID: 39923680. doi:10.1016/j.ygyno.2025.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。